ARS Pharmaceuticals, Inc. SPRY Contract Liabilities, Non-Current
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s contract liabilities, non-current.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s contract liabilities, non-current?
- ARS Pharmaceuticals, Inc. (SPRY) reported contract liabilities, non-current of $978K in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s contract liabilities, non-current changed year-over-year?
- ARS Pharmaceuticals, Inc.'s contract liabilities, non-current decreased by 27.0% year-over-year, from $1.34M to $978K.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s contract liabilities, non-current?
- Over 4 years (2021 to 2025), ARS Pharmaceuticals, Inc.'s contract liabilities, non-current has grown at a -21.6% compound annual growth rate (CAGR), from $3M to $1.13M.